Patents by Inventor Nilesh Parikh
Nilesh Parikh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12290504Abstract: Certain embodiments of the present disclosure provide storage-stable, aqueous pharmaceutical formulations, suitable for oral administration, that contain a therapeutically effective amount of that is from 2% w/v to 7.5% w/v topiramate, from 45% w/v to 75% w/v PEG 400, from 6% w/v to 12% w/v water, balance glycerol. In some embodiments, such formulations further comprise a sweetener (e.g., sucralose) and/or a flavorant (e.g., berry flavor).Type: GrantFiled: April 11, 2023Date of Patent: May 6, 2025Assignee: TaP Pharmaceuticals AGInventors: Nilesh Parikh, William Hite, Kartik Shah
-
Patent number: 12128054Abstract: Aqueous pharmaceutical compositions, suitable for topical ophthalmic administration to a mammal, that comprise a therapeutically effective amount of a prostaglandin, less than 0.3% w/v, and no added benzalkonium chloride, are provided. Such compositions are useful in methods comprising their topical administration to mammalian subjects, e.g., humans and reducing intraocular pressure and/or ocular hyperemia in the patient. Such compositions are also useful in methods comprising their topical administration to mammalian subjects, e.g., humans and promoting eyelash growth in the patient.Type: GrantFiled: October 26, 2022Date of Patent: October 29, 2024Assignee: FAMYGEN LIFE SCIENCES, INC.Inventors: William Hite, Nilesh Parikh
-
Publication number: 20240342132Abstract: Certain embodiments of the present disclosure provide storage-stable, aqueous pharmaceutical formulations, suitable for oral administration, that contain a therapeutically effective amount of that is from 2% w/v to 7.5% w/v topiramate, from 45% w/v to 75% w/v PEG 400, from 6% w/v to 12% w/v water, balance glycerol. In some embodiments, such formulations further comprise a sweetener (e.g., sucralose) and/or a flavorant (e.g., berry flavor).Type: ApplicationFiled: April 11, 2023Publication date: October 17, 2024Applicant: TaP Pharmaceuticals, AGInventors: Nilesh PARIKH, William HITE, Kartik SHAH
-
Patent number: 12109188Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain a therapeutically effective amount of topiramate that is from 50 mg/ml to 100 mg/ml and amounts of polyethylene glycol (“PEG”) 400 and glycerol sufficient to result in a greater than a prior art taught calculated maximum amount of the topiramate being in the solution phase of the formulation, at room temperature.Type: GrantFiled: March 24, 2023Date of Patent: October 8, 2024Inventors: Nilesh Parikh, William Hite
-
Publication number: 20240325349Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain a therapeutically effective amount of topiramate that is from 50 mg/ml to 100 mg/ml and amounts of polyethylene glycol (“PEG”) 400 and glycerol sufficient to result in a greater than a prior art taught calculated maximum amount of the topiramate being in the solution phase of the formulation, at room temperature.Type: ApplicationFiled: March 24, 2023Publication date: October 3, 2024Applicant: TaP Pharmaceuticals, AGInventors: Nilesh Parikh, William Hite
-
Patent number: 12042491Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain from 10 mg/ml to 100 mg/ml of a cinchona alkaloid or a quinolone compound, e.g. chloroquine or hydroxychloroquine, a solvent that is at least one of a glycerin, a propylene glycol (PG), and a polyethylene glycol (PEG); and a carbonate. In such formulations, the solvent and the carbonate are present in amounts sufficient to promote resistance to hydrogen peroxide mediated degradation of the cinchona alkaloid or quinoline.Type: GrantFiled: December 30, 2022Date of Patent: July 23, 2024Assignee: TaP Pharmaceuticals AGInventors: Nilesh Parikh, William Hite
-
Publication number: 20240238270Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain from 10 mg/ml to 100 mg/ml of a cinchona alkaloid or a quinolone compound, e.g. chloroquine or hydroxychloroquine, a solvent that is at least one of a glycerin, a propylene glycol (PG), and a polyethylene glycol (PEG); and a carbonate. In such formulations, the solvent and the carbonate are present in amounts sufficient to promote resistance to hydrogen peroxide mediated degradation of the cinchona alkaloid or quinoline.Type: ApplicationFiled: December 30, 2022Publication date: July 18, 2024Applicant: TaP Pharmaceuticals, AGInventors: Nilesh PARIKH, William HITE
-
Publication number: 20240226086Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain from 1 mg/ml to 300 mg/ml of chloroquine, hydroxychloroquine, or pharmaceutically acceptable salt(s) thereof and a solvent that is one or more of a glycerin, a propylene glycol, and a polyethylene glycol. Such formulations are free of added water and contain an amount of the the solvent is present sufficient to result in the chloroquine, hydroxychloroquine, or pharmaceutically acceptable salt thereof being in the solution phase of the formulation.Type: ApplicationFiled: December 29, 2022Publication date: July 11, 2024Applicant: TaP Pharmaceuticals, AGInventors: Nilesh PARIKH, William HITE
-
Patent number: 12023344Abstract: The disclosure provides pharmaceutical topical otic, ophthalmic, or nasal aqueous suspension formulations that comprise a corticosteroid; a chelating agent; a xanthan gum; an ionic tonicity agent; a pH from 5 to 6; and balance water. Such formulations comprise amounts of each of the xanthan gum and the ionic tonicity agent that together result in the formulation having: (i) a viscosity of from 4000 centipoises (“cps”) to 8000 centipoises (“cps”), and (ii) an osmolality of from 250 milliosmoles (“mOsm”) to 350 mOsm, and (iii) are readily redispersible.Type: GrantFiled: May 25, 2022Date of Patent: July 2, 2024Assignee: FamyGen Life Sciences, Inc.Inventors: William Hite, Nilesh Parikh, Kapil Swain, Jonathan Moreno
-
Publication number: 20240156833Abstract: Aqueous pharmaceutical compositions, suitable for topical ophthalmic administration to a mammal, that comprise a therapeutically effective amount of a prostaglandin, less than 0.3% w/v, and no added benzalkonium chloride, are provided. Such compositions are useful in methods comprising their topical administration to mammalian subjects, e.g., humans and reducing intraocular pressure and/or ocular hyperemia in the patient. Such compositions are also useful in methods comprising their topical administration to mammalian subjects, e.g., humans and promoting eyelash growth in the patient.Type: ApplicationFiled: October 26, 2022Publication date: May 16, 2024Inventors: William Hite, Nilesh Parikh
-
Patent number: 11980685Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain an amount of a tafamidis of from 0.5 mg/ml to 20 mg/ml, water, and an amount of an alkaline pH modifier that yields a content of the tafamidis solubilized in the water of from 0.5 mg/ml to 19.8 mg/ml.Type: GrantFiled: December 23, 2022Date of Patent: May 14, 2024Assignee: TaP Pharmaceuticals, AGInventors: Nilesh Parikh, William Hite
-
Patent number: 11878081Abstract: Certain embodiments of the present disclosure provide pharmaceutical, unit-dose formulations, suitable for oral administration, that contain from 1% w/w to 20% w/w of a tafamidis-organic acid (such as adipic acid, glutaric acid, or fumaric acid) co-crystal; from 0.25% w/w to 2.5% w/w of an organic acid dissolution enhancer. Such formulations release, within 15 minutes in ¾ strength FeSSIF pH 5.8 or in FaSSIF+0.1% polysorbate 80 pH 6.5, at least 85% of the total tafamidis of the formulation.Type: GrantFiled: December 23, 2022Date of Patent: January 23, 2024Assignee: TaP Pharmaceuticals AGInventors: Nilesh Parikh, William Hite
-
Publication number: 20240000801Abstract: The disclosure provides pharmaceutical topical otic, ophthalmic, or nasal aqueous suspension formulations that comprise a corticosteroid; a chelating agent; a xanthan gum; an ionic tonicity agent; a pH from 5 to 6; and balance water. Such formulations comprise amounts of each of the xanthan gum and the ionic tonicity agent that together result in the formulation having: (i) a viscosity of from 4000 centipoises (“cps”) to 8000 centipoises (“cps”), and (ii) an osmolality of from 250 milliosmoles (“mOsm”) to 350 mOsm, and (iii) are readily redispersible.Type: ApplicationFiled: May 25, 2022Publication date: January 4, 2024Inventors: William Hite, Nilesh Parikh, Kapil Swain, Jonathan Moreno
-
Patent number: 11833138Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain glycerol and an amount of apixaban in the solution phase of the formulations of from 0.5 mg/ml to 6 mg/ml.Type: GrantFiled: January 30, 2023Date of Patent: December 5, 2023Assignee: TaP Pharmaceuticals AGInventors: Nilesh Parikh, William Hite
-
Patent number: 11439760Abstract: Embodiments of this invention provide syringes calibrated for use with a predetermined liquid medication having an active pharmaceutical ingredient (API) at a particular weight per unit volume (w/v) concentration. Such syringes comprising a plunger and a barrel are configured such that the plunger, and/or an end portion of the plunger, is sealingly receivable through an opening at one end the barrel and within the barrel and slidingly moveable lengthwise within the barrel. This configuration allows formation of a reservoir inside the barrel into which the liquid medication may be loaded through an intake opening for the liquid medication at the other end of the barrel. Syringe barrels according to this invention possess line increments that form two or more graduated scales of API weight dosages extending lengthwise along the barrels. The increment lines provide for highly precise and accurate measurement of fine-increment weight dosages of the API.Type: GrantFiled: July 14, 2019Date of Patent: September 13, 2022Inventors: Nilesh Parikh, William Hite
-
Publication number: 20210008291Abstract: Embodiments of this invention provide syringes calibrated for use with a predetermined liquid medication having an active pharmaceutical ingredient (API) at a particular weight per unit volume (w/v) concentration. Such syringes comprising a plunger and a barrel are configured such that the plunger, and/or an end portion of the plunger, is sealingly receivable through an opening at one end the barrel and within the barrel and slidingly moveable lengthwise within the barrel. This configuration allows formation of a reservoir inside the barrel into which the liquid medication may be loaded through an intake opening for the liquid medication at the other end of the barrel. Syringe barrels according to this invention possess line increments that form two or more graduated scales of API weight dosages extending lengthwise along the barrels. The increment lines provide for highly precise and accurate measurement of fine-increment weight dosages of the API.Type: ApplicationFiled: July 14, 2019Publication date: January 14, 2021Inventors: Nilesh Parikh, William Hite
-
Publication number: 20180325852Abstract: Embodiments of the present invention provide pharmaceutical compositions in unit dosage form that comprise a therapeutically effective amount of levothyroxine sodium; an antioxidant in an amount sufficient to stabilize the levothyroxine sodium against oxidation; an amount of one or more of a monosaccharide, a disaccharide, and an oligosaccharide sufficient to stabilize the levothyroxine sodium; and two or more of a filler, a binder, and a lubricant.Type: ApplicationFiled: July 24, 2018Publication date: November 15, 2018Inventors: Nilesh Parikh, William C. Hite
-
Publication number: 20170333688Abstract: The present invention provides devices for dispensing topical pharmaceutical compositions. In some embodiments, the dispensing device possesses a reservoir for storing the composition and means for metering the composition. In some embodiments, such reservoirs are: i. made from, or substantially lined with, a material that opaque and/or substantially nondepleting of at least one component of the composition; ii. optionally, volumetrically compressible; and iii. fitted with the means for metering the composition. And the means for metering are adapted to measure a fixed amount of the composition for application to a dermal region of a user of the device. In some embodiments, the compositions has a specific gravity in the range of from about 0.85 to about 1.20 at about room temperature and comprises a medicament; a thickening agent; and a solvent, and optionally a skin penetration enhancer and/or a deodorant.Type: ApplicationFiled: November 11, 2015Publication date: November 23, 2017Inventors: Nilesh Parikh, William C Hite
-
Publication number: 20160331711Abstract: Embodiments of the present invention provide pharmaceutical compositions in unit dosage form that comprise a therapeutically effective amount of levothyroxine sodium; an antioxidant in an amount sufficient to stabilize the levothyroxine sodium against oxidation; an amount of one or more of a monosaccharide, a disaccharide, and an oligosaccharide sufficient to stabilize the levothyroxine sodium; and two or more of a filler, a binder, and a lubricant.Type: ApplicationFiled: July 28, 2016Publication date: November 17, 2016Inventors: Nilesh Parikh, William C. Hite
-
Patent number: 9393243Abstract: Embodiments of the invention provide pharmaceutical compositions of ciprofloxacin formulated for topical application to a body surface and for having at least localized antibacterial activity. In some embodiments, the compositions are further formulated for localized anti-inflammatory activity, anti-fungal activity, anti-viral activity, or combinations thereof. Such compositions possess a therapeutically effective amount of a non-betaine form ciprofloxacin (e.g., ciprofloxacin hydrochloride monohydrate); one of a pH adjusting agent and a preservative; water; and a pH from about 5.5 to about 10. In some embodiments, such compositions may be free or free of added skin permeation enhancer and/or contain a betaine form ciprofloxacin.Type: GrantFiled: July 14, 2015Date of Patent: July 19, 2016Inventors: Nilesh Parikh, William Crawford Hite